Clovis Oncology Q4 Loss Widens - Quick Facts

(RTTNews) - Clovis Oncology, Inc. (CLVS) reported a net loss for the fourth quarter of $29.20 million or $0.92 per share, wider than $21.06 million or $0.81 per share in the prior-year quarter.

On average, six analysts polled by Thomson Reuters expected the company to report a loss of $0.78 per share for the quarter. Analysts' estimates typically exclude special items.

The company has not reported any revenues for the quarter.

Research and development expenses grew to $22.5 million from $18.3 million in the year-ago quarter.

Looking ahead, the company noted that CO-1686 Phase 2 expansion cohorts increased in size to about 300 patients. The revealed the potential to accelerate New Drug Application (NDA) for its first New Drug Application (NDA) submission for 2015.